Catalist:42CPharmaceuticals
Ix Biopharma (Catalist:42C) Narrowing H1 EPS Loss Challenges Bearish Earnings Narratives
iX Biopharma (Catalist:42C) has reported H1 2026 revenue of S$3.2 million with a basic EPS loss of S$0.00226, while net income excluding extraordinary items came in at a loss of S$2.1 million, setting a cautious tone for the latest update. Over the last three reported halves, revenue has moved from S$3.7 million in H1 2025 to S$4.1 million in H2 2025 and S$3.2 million in H1 2026. Over the same period, basic EPS losses shifted from S$0.00717 in H1 2025 to S$0.00442 in H2 2025 and S$0.00226 in...